View Author
scopus: 7401730068

Richardson, P.G.

(Paul Gerard Richardson)


patient bortezomib myeloma dexamethasone response study therapy trial treatment analysis blood neuropathy signi journal survival thalidomide phase richardson cancer incidence factor disease signi ficantly high-dose score grade high-dose dexamethasone british journal result month table myeloma patients sample response rate cycle baseline subgroups group research thrombosis ef ficacy lenalidomide combination bene fit bortezomib arm metaphase cytogenetics quality impairment haematology event ficantly prognostic progression dexamethasone arm british apex trial expression number population prophylaxi impact summit ficant cytogenetic england journal anderson barlogie oncology barlogie b dose modi fication chemotherapy venou marrow figure venous thromboembolism jagannath method warfarin 5- week cycles hospital




10 Most Recent Publications

Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group (Article)
Fernández De Larrea, C. Kyle, R. Kumar, S. Mahindra, A. Comenzo, R.L. Palumbo, A. Mazumber, A. Anderson, K.C. Richardson, P.G. Badros, A.Z. Caers, J. Cavo, M. Durie, B.G.M. Leleu, X. Dimopoulos, M.A. Chim, C.S. Schots, R. Noeul, A. Fantl, D. Mellqvist, U.H. Landgren, O. Chanan-Khan, A. Moreau, P. Ludwig, H. Fonseca, R. Merlini, G. Lahuerta, J.J. Bladé, J. Orlowski, R.Z. Shah, J.J. Usmani, S.M. Vesole, D. Hajek, R. San Miguel, J-F. Sezer, O. Sonneveld, P.
2013-04-01
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline (Article)
Richardson, P.G. Sonneveld, P. Bladé, J. Boccadoro, M. Cavenagh, J. Boral, A.L. Esseltine, D-L. Wen, P.Y. Amato, A.A. Anderson, K.C. San Miguel, J-F. Schuster, M.W. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H. Reece, D.
2009-03-01
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: Results from the APEX study (Article)
Lee, S.J. Richardson, P.G. Anderson, K.C. Sonneveld, P. Schuster, M.W. Irwin, D. San Miguel, J-F. Crawford, B.T. Massaro, J. Dhawan, R. Gupta, S.
2008-11-01
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma (Article)
Lonial, S. Richardson, P.G. Anderson, K.C. Harousseau, J-L. San Miguel, J-F. Sonneveld, P. Schuster, M.W. Bladé, J. Cavenagh, J. Rajkumar, S.V. Jakubowiak, A.J. Esseltine, D-L.
2008-10-01
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma (Article)
Niesvizky, R. Richardson, P.G. Harousseau, J-L. Boral, A.L. Esseltine, D-L. Anderson, K.C. Bladé, J. Rajkumar, S.V. Coleman, M. Rosiñol, L. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T.
2008-10-01
Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study (Article)
San Miguel, J-F. Richardson, P.G. Goldschmidt, H. Reece, D. Bladé, J. Boccadoro, M. Cavenagh, J. Neuwirth, R. Boral, A.L. Esseltine, D-L. Anderson, K.C. Sonneveld, P. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S.
2008-04-01
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (Article)
Palumbo, A. Rajkumar, S.V. Attal, M. Belch, A. Knop, S. Joshua, D. Sezer, O. Ludwig, H. Vesole, D. Bladé, J. Kyle, R. Westin, J. Dimopoulos, M.A. Weber, D. Bringhen, S. Niesvizky, R. Waage, A. Lilienfeld-Toal, M. Von Lonial, S. Morgan, G. Orlowski, R.Z. Shimizu, K. Anderson, K.C. Richardson, P.G. Boccadoro, M. Durie, B.G.M. Sonneveld, P. Hussein, M. San Miguel, J-F. Barlogie, B. Harousseau, J-L. Zonder, J.A. Cavo, M. Zangari, M.
2008-02-01
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial (Article)
Richardson, P.G. Sonneveld, P. Reece, D. San Miguel, J-F. Bladé, J. Boccadoro, M. Cavenagh, J. Alsina, M. Rajkumar, S.V. Lacy, M. Jakubowiak, A.J. Dalton, W. Schuster, M.W. Boral, A.L. Esseltine, D-L. Schenkein, D. Anderson, K.C. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H.
2007-11-15
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients (Article)
Zangari, M. Esseltine, D-L. Cavallo, F. Neuwirth, R. Elice, F. Burns, M.J. Yaccoby, S. Richardson, P.G. Sonneveld, P. Tricot, G.
2007-09-01
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma (Article)
Richardson, P.G. Sonneveld, P. Cavenagh, J. Anderson, K.C. Schuster, M.W. Irwin, D. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. San Miguel, J-F.
2007-06-01
  • rss icon RSS Publication Feed
  • foaf icon FOAF Profile